Products

Products

Home page

API

Gadobutrol Monohydrate

Varenicline Tartrate

Gadoterate Meglumine

Fosaprepitant Dimeglumine

News Center

Viwit Pharmaceuticals' Sterile Production Facility Successfully Passes U.S. FDA Inspection

Viwit Pharmaceutical's Phenylephrine Hydrochloride Injection Officially Receives Official Approval by China NMPA

Viwit Pharmaceuticals’ Brimonidine tartrate and Timolol maleate eye drops receive Official Approval by China NMPA

Viwit's Nitroglycerin Sublingual Tablets Approved by FDA

Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated"

Viwit Pharmaceutical Co. Ltd. announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable contrast agents in the US.

← Back to previous page

DOTA

Product Name:

DOTA

CAS#:

60239-18-1

Specification:In-house

Country/region:China, USA

Character/Appearance:White or off-white powder.

Assay:98.0%-102.0%

Applications:A gadolinium-based contrast agent.

Package:Pack as per customer requirement.

Storage:Airtight, store below 25℃.

VIWIT

Technical Support:China Enterprise Cross-border | SEO Tags

【Business License】

Search